Arthur Vander Stichele

Dr. Arthur Vander Stichele

Urology, KU Leuven, Leuven, Belgium
+2

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GDGaëtan Devos
Gaëtan Devos
CBCharlien Berghen
Charlien Berghen
HEHenri Van Eecke
Henri Van Eecke
ASArthur Vander Stichele
Arthur Vander Stichele
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
Steven JoniauSteven Joniau
Steven Joniau
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials.

28 October 2022 in International Journal of Urology
Verified
Journal Article
Closed access
HEHenri Van Eecke
Henri Van Eecke
GDGaëtan Devos
Gaëtan Devos
BVBram Vansevenant
Bram Vansevenant
ASArthur Vander Stichele
Arthur Vander Stichele
Wout DevliesWout Devlies
Wout Devlies
Steven JoniauSteven Joniau
Steven Joniau

14 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASArthur Vander Stichele
Arthur Vander Stichele
BCBen Van Cleynenbreugel
Ben Van Cleynenbreugel
Background/Objectives: White-light cystoscopy remains central to bladder cancer detection and surveillance, but diagnostic uncertainty persists in detecting flat lesions, particularly carcinoma in situ, distinguishing inflammatory mimics, and targeting biopsies. Optical spectroscopy and spectral imaging may provide objective tissue information beyond visual inspection. This scoping review mapped the diagnostic evidence and translational readiness of these technologies. Methods: A scoping review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). PubMed, Embase and Web of Science were searched from inception to 31 July 2026. Eligible articles evaluated wavelength-dependent optical signals directly in human bladder tissue in clinically relevant in vivo or ex vivo settings. Related articles with the same, overlapping or expanded datasets were grouped into study families. Results: Forty-seven articles were organised into 39 study families. Raman spectroscopy showed the clearest progression from ex vivo discrimination to in vivo cystoscopic feasibility and device development. Fluorescence and reflectance provided early in vivo evidence, although specificity was often limited by inflammation and benign changes. Infrared and near-infrared techniques remained mainly specimen-based, while multimodal systems were evaluated mostly ex vivo. Evidence for spectral imaging was limited, and no clinically integrated endoscopic hyperspectral-imaging study meeting the criteria was identified. Conclusions: Optical spectroscopy and spectral imaging show diagnostic potential for bladder cancer tissue characterisation, but evidence remains heterogeneous and insufficient for routine implementation. Among the included techniques, Raman spectroscopy appears most translationally mature, whereas wide-field spectral imaging remains underdeveloped. Future studies should prioritise prospective in vivo evaluation, standardised acquisition, histopathological correlation, external patient-level validation and clinically meaningful endpoints.